DKK1,481.00
0.20% yesterday
Copenhagen, Jun 13, 04:59 pm CET
ISIN
DK0010272202
Symbol
GMAB
Sector

Genmab A/S Stock price

DKK1,481.00
+211.00 16.61% 1M
+42.50 2.95% 6M
-11.50 0.77% YTD
-343.00 18.80% 1Y
-519.00 25.95% 5Y
+895.50 152.95% 10Y
+1,365.00 1,176.72% 20Y
Copenhagen, Closing price Fri, Jun 13 2025
-3.00 0.20%
ISIN
DK0010272202
Symbol
GMAB
Sector

Key metrics

Market capitalization DKK91.26b
Enterprise Value DKK88.18b
P/E (TTM) P/E ratio 39.84
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 11.10
P/S ratio (TTM) P/S ratio 11.49
P/B ratio (TTM) P/B ratio 17.75
Revenue growth (TTM) Revenue growth -55.29%
Revenue (TTM) Revenue DKK7.94b
EBIT (operating result TTM) EBIT DKK2.48b
Free Cash Flow (TTM) Free Cash Flow DKK-90.38m
Cash position DKK3.23b
EPS (TTM) EPS DKK37.25
P/E forward 14.75
P/S forward 3.89
EV/Sales forward 3.76
Show more

Is Genmab A/S a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Genmab A/S Stock Analysis

Unlock Scores for Free

Analyst Opinions

24 Analysts have issued a Genmab A/S forecast:

17x Buy
71%
6x Hold
25%
1x Sell
4%

Analyst Opinions

24 Analysts have issued a Genmab A/S forecast:

Buy
71%
Hold
25%
Sell
4%

Financial data from Genmab A/S

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
7,942 7,942
55% 55%
100%
- Direct Costs 325 325
21% 21%
4%
7,617 7,617
42% 42%
96%
- Selling and Administrative Expenses 1,342 1,342
61% 61%
17%
- Research and Development Expense 3,615 3,615
56% 56%
46%
2,556 2,556
-
32%
- Depreciation and Amortization 79 79
-
1%
EBIT (Operating Income) EBIT 2,477 2,477
56% 56%
31%
Net Profit 2,382 2,382
56% 56%
30%

In millions DKK.

Don't miss a Thing! We will send you all news about Genmab A/S directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark.

Head office Denmark
CEO Jan Winkel
Employees 2,682
Founded 1998
Website www.genmab.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today